Codexis Licenses Enzyme Portfolio to Alphazyme, Focusing on Core Businesses

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, has announced a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC, part of Maravai LifeSciences. This strategic move enables Codexis to focus on its core businesses of pharmaceutical manufacturing and the development of its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ platform.

The agreement includes licenses for several enzymes in Codexis' life science enzyme portfolio, such as the HiFi DNA Polymerase, HiTemp Reverse Transcriptase, and HiRev Isothermal Polymerase. These enzymes were previously directed towards genomics and diagnostics applications but have been divested as part of Codexis' strategic shift announced in July 2023.


This licensing deal allows Codexis to maintain its focus on maximizing near-term commercial opportunities and strategic priorities. Key milestones for the ECO Synthesis™ platform are expected to be achieved this fiscal year, while delivering double-digit product revenue growth and maintaining a path to positive cash flow around the end of 2026.

The partnership with Alphazyme, a premier partner for industrial-scale molecular biology enzymes, will enhance Codexis' commercial reach in the genomics and diagnostics market segments. Alphazyme's existing genomics enzyme portfolio and sales force will facilitate a smooth transition for Codexis' customers, with no change in manufacturing supply.


In terms of financial impact, this licensing deal is expected to contribute to Codexis' revenue growth and help the company achieve its cash flow projections. By divesting non-core assets, Codexis can allocate more resources to its Pharmaceutical Manufacturing business and the ECO Synthesis™ platform, driving long-term growth and market expansion.

This collaboration with Alphazyme is another transaction in Codexis' strategy to divest non-core assets, following its strategic shift to focus on its core businesses. By leveraging Alphazyme's experience and industry knowledge, Codexis can enhance the commercialization of its life science and diagnostic enzymes while maintaining its focus on the growth of its Pharmaceutical Manufacturing business and the ECO Synthesis™ platform.